489 related articles for article (PubMed ID: 19996339)
1. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
Ratjen F; Munck A; Kho P; Angyalosi G;
Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339
[TBL] [Abstract][Full Text] [Related]
2. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
Tramper-Stranders GA; Wolfs TF; van Haren Noman S; van Aalderen WM; Nagelkerke AF; Nuijsink M; Kimpen JL; van der Ent CK
Thorax; 2010 Oct; 65(10):915-20. PubMed ID: 20729233
[TBL] [Abstract][Full Text] [Related]
3. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Hansen CR; Pressler T; Høiby N
J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis.
Proesmans M; Vermeulen F; Boulanger L; Verhaegen J; De Boeck K
J Cyst Fibros; 2013 Jan; 12(1):29-34. PubMed ID: 22762867
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.
Stanojevic S; Waters V; Mathew JL; Taylor L; Ratjen F
J Cyst Fibros; 2014 Mar; 13(2):172-8. PubMed ID: 24091166
[TBL] [Abstract][Full Text] [Related]
6. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
7. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols.
Taccetti G; Bianchini E; Cariani L; Buzzetti R; Costantini D; Trevisan F; Zavataro L; Campana S;
Thorax; 2012 Oct; 67(10):853-9. PubMed ID: 22379071
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM
J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
[TBL] [Abstract][Full Text] [Related]
9. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
Ratjen F; Brockhaus F; Angyalosi G
J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
[TBL] [Abstract][Full Text] [Related]
10. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
[TBL] [Abstract][Full Text] [Related]
11. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
Griese M; Müller I; Reinhardt D
Eur J Med Res; 2002 Feb; 7(2):79-80. PubMed ID: 11891148
[TBL] [Abstract][Full Text] [Related]
12. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
Møller NE; Høiby N
Scand J Infect Dis Suppl; 1981; 29():87-91. PubMed ID: 6458884
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
[TBL] [Abstract][Full Text] [Related]
15. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
Gibson RL; Emerson J; Mayer-Hamblett N; Burns JL; McNamara S; Accurso FJ; Konstan MW; Chatfield BA; Retsch-Bogart G; Waltz DA; Acton J; Zeitlin P; Hiatt P; Moss R; Williams J; Ramsey BW
Pediatr Pulmonol; 2007 Jul; 42(7):610-23. PubMed ID: 17534969
[TBL] [Abstract][Full Text] [Related]
16. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.
Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R
Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS.
Sands D; Sapiejka E; Gąszczyk G; Mazurek H;
J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients.
Govoni M; Poli G; Acerbi D; Santoro D; Cicirello H; Annoni O; Ružička J
Pulm Pharmacol Ther; 2013 Apr; 26(2):249-55. PubMed ID: 23232039
[TBL] [Abstract][Full Text] [Related]
19. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
20. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
Woodward TC; Brown R; Sacco P; Zhang J
J Med Econ; 2010; 13(3):492-9. PubMed ID: 20670159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]